Literature DB >> 6651238

Prognosis of ocular myasthenia.

C T Bever, A V Aquino, A S Penn, R E Lovelace, L P Rowland.   

Abstract

A retrospective study of 108 patients with myasthenia gravis who had solely ocular symptoms and signs at onset was carried out to identify factors influencing prognosis. Increasing duration of pure ocular myasthenia was associated with a decreasing risk of late generalized symptoms; only 9 (15%) of the observed generalizations occurred after more than 2 years of solely ocular symptoms. Increasing age at onset was associated with greater risk of respiratory crisis or death caused by myasthenia, whereas patients younger at onset had a greater chance of a benign outcome. Neither systemic curare tests nor responses to repetitive nerve stimulation had prognostic value.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6651238     DOI: 10.1002/ana.410140504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

1.  Ophthaproblem. Ocular myasthenia gravis.

Authors:  Stephanie Baxter; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2002-11       Impact factor: 3.275

Review 2.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

4.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Authors:  Michael Benatar; Michael P Mcdermott; Donald B Sanders; Gil I Wolfe; Richard J Barohn; Richard J Nowak; Michael Hehir; Vern Juel; Hans Katzberg; Rabi Tawil
Journal:  Muscle Nerve       Date:  2016-01-27       Impact factor: 3.217

Review 5.  Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.

Authors:  Kai Zhu; Jiaoxing Li; Xin Huang; Wei Xu; Weibin Liu; Jiaxin Chen; Pei Chen; Huiyu Feng
Journal:  Neurol Sci       Date:  2017-07-13       Impact factor: 3.307

6.  Bilateral intracavernous carotid aneurysms presenting as pseudo-ocular myasthenia gravis.

Authors:  J S Mindel; J Z Charney
Journal:  Trans Am Ophthalmol Soc       Date:  1989

7.  Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Authors:  Mengcui Gui; Xuan Luo; Jing Lin; Yue Li; Min Zhang; Xiaofan Zhang; Mingshan Yang; Wei Wang; Bitao Bu
Journal:  J Neurol       Date:  2015-01-15       Impact factor: 4.849

8.  Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Authors:  M J Kupersmith; G Ying
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

9.  The contribution of oculography to early diagnosis of myasthenia gravis. A study of saccadic eye movements using the infrared reflection method in 22 cases.

Authors:  C E Sollberger; O Meienberg; H P Ludin
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

10.  Mycophenolate mofetil for ocular myasthenia.

Authors:  Jane W Chan
Journal:  J Neurol       Date:  2008-02-29       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.